Sep. 17 at 9:29 AM
$CALC Here we have a completely different story: clinical-stage biotech, where the major catalyst is the development of Auxora.
The company is advancing Auxora for pulmonary arterial hypertension (PAH) and acute pancreatitis. Regarding pancreatitis, the FDA has already aligned with CalciMedica on the design of the upcoming Phase 2b trial; the primary endpoint will measure whether Auxora reduces the incidence of new-onset severe respiratory failure.
💰 Additionally, CalciMedica secured up to approximately
$49 million in funding to advance its pulmonary hypertension program. The company expects proof-of-concept data for Auxora in PAH and the filing of an IND for its oral candidate, CM5480, around mid-2027.
And very recent news has eliminated an immediate concern: on September 15, Nasdaq confirmed that CALC had regained compliance with the
$1 minimum bid price requirement after maintaining a closing price above that level for 10 consecutive sessions.
